The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Spending on new drug development1
Abstract
This paper replicates DiMasi et al. (J. Health Econ. 2003; 22: 151–185; Drug Inf. J. 2004; 38: 211–223) estimates of expenditure on new drug development using publicly available data. The paper estimates that average expenditure on drugs in human clinical trials is around $27m per year, with $17m per year on drugs in Phase I, $34m on drugs in Phase II and $27m per year on drugs in Phase III of the human clinical trials. The paper's estimated expenditure on new drug development is somewhat greater than suggested by the survey results presented in DiMasi et al. (J. Health Econ. 2003; 22: 151–185; Drug Inf. J. 2004; 38: 211–223). The paper combines a 12‐year panel of research and development expenditure for 183 publicly traded firms in the pharmaceutical industry with panel of drugs in human clinical trials for each firm over the same period. The paper estimates drug expenditure by estimating the relationship between research and development expenditure and the number of drugs in development for 1682 company/years (183 firms multiplied by the number of years for which we have financial and drug development information). The paper also estimates expenditure on drugs in various therapeutic categories. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Scale, Scope, and Spillovers: The Determinants of Research Productivity in Drug Discovery
Henderson, R., & Cockburn, I. (1996) · The RAND Journal of Economics · doi:10.2307/2555791 · Cited by 1,388
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
Adams, C. P., & Brantner, V. V. (2006) · Health Affairs · doi:10.1377/hlthaff.25.2.420 · Cited by 907
Self-citationProductivity in pharmaceutical–biotechnology R&D: the role of experience and alliances
Danzon, P. M., Nicholson, S., & Pereira, N. S. (2005) · Journal of Health Economics · doi:10.1016/j.jhealeco.2004.09.006 · Cited by 290
Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
Cockburn, I., & Henderson, R. M. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00108-4 · Cited by 220
R&D Costs and Returns by Therapeutic Category
DiMasi, J. A., Grabowski, H. G., & Vernon, J. (2004) · Drug Information Journal · doi:10.1177/009286150403800301 · Cited by 120
Extraordinary claims require extraordinary evidence
Light, D. W., & Warburton, R. (2005) · Journal of Health Economics · doi:10.1016/j.jhealeco.2005.07.001 · Cited by 79
Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
Danzon, P. M., Epstein, A. J., & Nicholson, S. (2004) · National Bureau of Economic Research · doi:10.3386/w10536 · Cited by 67
Pharmaceutical Development Phases
Abrantes-Metz, R. M. (2006) · Journal of Pharmaceutical Finance Economics & Policy · doi:10.1300/j371v14n04_03 · Cited by 36
New Drug Development: Estimating Entry from Human Clinical TrialsPreprint
Adams, C., & Brantner, V. V. (2003) · SSRN Electronic Journal · doi:10.2139/ssrn.428040 · Cited by 28
Self-citation
Cited by
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
The cost of drug development: A systematic review
Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C., & Greyson, D. (2011) · Health Policy · doi:10.1016/j.healthpol.2010.12.002 · Cited by 510
Cunningham, C., Ederer, F., & Ma, S. (2021) · Journal of Political Economy · doi:10.1086/712506 · Cited by 452
Metadata
- Authors
- Adams, C. P., & Brantner, V. V.
- Venue
- Health Economics
- Publisher
- Wiley
- Published
- 2009-02-26
- Volume
- 19
- Issue
- 2
- Pages
- 130-141
- ISSN
- 1057-9230 (ISSN-L)
- 1099-1050
- OpenAlex
- W3125730391
- Cited by
- 277
- References
- 10
- FWCI
- 60.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.